Growth Momentum CRA reported record first-quarter 2026 revenue of $201 million, a 10.5% year-over-year increase driven by broad-based growth across eight practices and North American and international operations. Sales opportunity: leverage the diversified practice strengths and global reach to cross-sell to existing clients and expand into high-growth sectors such as healthcare, financial services, and regulatory consulting.

Antitrust Expansion The addition of Hitesh Makhija to the Antitrust & Competition Economics Practice signals a sharpened capability in mergers and competition matters. Sales play: target clients undergoing mergers or antitrust investigations in pharma, tech, and consumer sectors, offering advanced economic analysis, expert testimony, and regulatory strategy.

Leadership Transitions Board leadership changes, with Christine Detrick named independent Lead Director after William Concannon's retirement, indicate governance continuity and potential new board-level advisory opportunities. Sales angle: cultivate relationships with C-suite and board buyers for governance risk, regulatory strategy, and strategic advisory engagements.

Pharma EFPIA CRA is increasingly active in the pharmaceutical sector, highlighted by EFPIA collaborations, and has formed program-management through partners like Applyists for administration and applicant support. Sales focus: pursue pharma associations and regulated industries as long-term clients, offering economic modeling, policy impact analyses, and managed education/program delivery services.

Global Tech Edge With a global delivery footprint and a tech stack including PyTorch, Mathematica, Drupal and cloud-based tooling, CRA can deliver scalable, data-driven economics and financial analyses for complex disputes and regulatory matters. Sales tactic: position CRA as a technologically-enabled partner for international projects, offering ongoing analytics, digital delivery, and monitoring capabilities.